Rosiglitazone elicits its protective functions against non-alcoholic fatty liver disease largely through the induction of adiponectin, which prevents mitochondria stresses by promoting GSK3beta activation and UCP2 upregulation, two pathways coordinating the glucose and lipid metabolism in liver [34]. This evidence concerns the gene GSK3B and metabolic dysfunction-associated steatotic liver disease.